Post COVID-19 condition of the Omicron variant of SARS-CoV-2

• Published in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 28; no. 11; pp. 1546 - 1551
• Main Authors: Morioka, S., Tsuzuki, S., Suzuki, M., Terada, M., Akashi, M., Osanai, Y., Kuge, C., Sanada, M., Tanaka, K., Maruki, T., Takahashi, K., Saito, S., Hayakawa, K., Teruya, K., Hojo, M., Ohmagari, N.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.11.2022; Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd
• Subjects: Long COVID; Omicron; Original; Post COVID-19 conditions; WHO definition; Post COVID-19 conditions; Omicron; Long COVID; WHO definition
• ISSN: 1341-321X; 1437-7780; 1437-7780
• DOI: 10.1016/j.jiac.2022.08.007

To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains. A single-center cross-sectional study. Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via telephone, and patients infected with other strains (control group) were surveyed via a self-reporting questionnaire. Data on patients’ characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted for at least 2 months, within 3 months of COVID-19 onset. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching. We conducted interviews for 53 out of 128 patients with Omicron and obtained 502 responses in the control group. After matching cases with controls, 18 patients from both groups had improved covariate balance of the factors: older adult, female sex, obesity, and vaccination status. There were no significant differences in the prevalence of each post COVID-19 condition between the two groups. The number of patients with at least one post COVID-19 condition in the Omicron and control groups were 1 (5.6%) and 10 (55.6%) (p = 0.003), respectively. The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with a larger sample size is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity.